Sun Pharmaceutical Industries Ltd.

Sun Pharmaceutical Industries is currently trading at Rs. 912.85, up by 14.65 points or 1.63% from its previous closing of Rs. 898.20 on the BSE.

The scrip opened at Rs. 909.90 and has touched a high and low of Rs. 915.00 and Rs. 902.25 respectively. So far 80,000 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1200.70 on 07-Apr-2015 and a 52 week low of Rs. 792.00 on 17-Oct-2014.

Last one week high and low of the scrip stood at Rs. 915.00 and Rs. 840.90 respectively. The current market cap of the company is Rs. 2,19,924.00 crore.

The promoters holding in the company stood at 54.71% while Institutions and Non-Institutions held 31.51% and 13.78% respectively.

Sun Pharmaceutical Industries’ wholly-owned subsidiary - Ranbaxy Pharmaceuticals Inc. (Ranbaxy), along with its partners, Cipher Pharmaceuticals Inc. (Cipher) and Galephar Pharmaceutical Research, Inc. (Galephar) have entered into a settlement agreement with Actavis Group (Actavis) that dismisses the patent litigation suit relating to Actavis’ Abbreviated New Drug Application (ANDA) for a generic version of Absorica (isotretinoin capsules).

As part of the settlement agreement, Ranbaxy, Cipher, and Galephar have entered into a non-exclusive license agreement with Actavis under which Actavis may begin selling its generic version of Absorica  in the US on December 27, 2020 (approximately nine months prior to the expiration of the patents in September 2021) or earlier under certain circumstances.

The settlement agreement is subject to review by the US Federal Trade Commission and the US Department of Justice.